TGFBI: A novel therapeutic target for cancer

Huimei Huang; Qinglai Tang; Shisheng Li; Yuexiang Qin; Gangcai Zhu

doi:10.1016/j.intimp.2024.112180

TGFBI: A novel therapeutic target for cancer

Int Immunopharmacol. 2024 May 10:134:112180. doi: 10.1016/j.intimp.2024.112180. Online ahead of print.

Authors

Huimei Huang¹, Qinglai Tang¹, Shisheng Li¹, Yuexiang Qin², Gangcai Zhu³

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
² Department of Otolaryngology-Head and Neck Surgery, The Third Xiangya Hospital, Central South University, Changsha, China.
³ Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: qianhudoctor@csu.edu.cn.

PMID: 38733822
DOI: 10.1016/j.intimp.2024.112180

Abstract

TGFBI, an extracellular matrix protein induced by transforming growth factor β, has been found to exhibit aberrant expression in various types of cancer. TGFBI plays a crucial role in tumor cell proliferation, angiogenesis, and apoptosis. It also facilitates invasion and metastasis in various types of cancer, including colon, head and neck squamous, renal, and prostate cancers. TGFBI, a prominent p-EMT marker, strongly correlates with lymph node metastasis. TGFBI demonstrates immunosuppressive effects within the tumor immune microenvironment. Targeted therapy directed at TGFBI shows promise as a potential strategy to combat cancer. Hence, a comprehensive review was conducted to examine the impact of TGFBI on various aspects of tumor biology, including cell proliferation, angiogenesis, invasion, metastasis, apoptosis, and the immune microenvironment. This review also delved into the underlying biochemical mechanisms to enhance our understanding of the research advancements related to TGFBI in the context of tumors.

Keywords: Cancer; Immune microenvironment; Metastasis; TGFBI.

Publication types

Review